Strict supervision of traditional Chinese medicine injection hundreds of pharmaceutical factories or near bankruptcy

After the Houttuynia event, the State Food and Drug Administration suspended the sale and use of seven kinds of related drugs Many enterprises are directly in the dilemma of returning and stopping production due to their excessive dependence on traditional Chinese medicine injection business In the event of Houttuynia cordata, nearly 100 enterprises' production lines were in the state of shutdown and half production, more than 10 enterprises were directly on the verge of bankruptcy, with a loss of about 2 billion yuan According to the report of time weekly, the injection of traditional Chinese medicine has become the largest market share in the field of traditional Chinese medicine In the market share of cardio cerebrovascular and anti-tumor Chinese patent medicine, the top 10 products account for 7 seats in total There are more than 50 kinds of commonly used traditional Chinese medicine injections, with an overall market scale of 25-30 billion yuan In recent five years, the compound growth rate is about 21%, which is significantly higher than the income growth rate of 15.78% of proprietary Chinese medicine and 18.23% of the whole drug market According to the data of the State Food and drug administration, at present, the number of drugs produced by domestic pharmaceutical enterprises is up to 160000, and the number of traditional Chinese medicine is close to 60000, while the number of traditional Chinese medicine injections is no more than 140, and only about 150 pharmaceutical enterprises are engaged in the production of traditional Chinese medicine injections Various listed pharmaceutical companies also rely on the traditional Chinese medicine injection business to varying degrees According to the situation of Chinese medicine injection production enterprises that have published the mid-2013 report, Shanghai Kaibao Chinese medicine injection revenue accounts for 99% of the total revenue, which is the most concentrated enterprise in its industry; the proportion of Xueshuantong of Zhongheng group also reaches a high of 88%; the proportion of HongRi pharmaceutical and Kangyuan pharmaceutical in 2013 accounts for 64% and 55% In fact, among the 55 listed companies of traditional Chinese medicine, only the time-honored enterprises such as pianzehuang and Yunnan Baiyao, which have the exclusive heavy-duty varieties, and the enterprises mainly engaged in traditional Chinese medicine injection, can maintain an annual growth rate of more than 30% In fact, as a symbol of modernization of traditional Chinese medicine, the safety of traditional Chinese medicine injection has been questioned According to the public data, adverse reactions of traditional Chinese medicine injections were reported 103000 times in 2012 At present, many hospitals hold a boycott attitude towards it because of frequent adverse reactions Doctors of Guangzhou first and third class hospital admit that the hospital has not used traditional Chinese medicine injection On the other hand, high profits drive the major pharmaceutical enterprises to increase investment in traditional Chinese medicine injection The 2015 edition of Chinese Pharmacopoeia has been revised, because of safety issues, the regulatory control of traditional Chinese medicine injections is also tightening step by step For enterprises, it will be impacted After the Houttuynia event, the State Food and Drug Administration suspended the sale and use of seven kinds of related drugs After the suspension, many enterprises directly fell into the dilemma of return and production suspension due to their excessive dependence on traditional Chinese medicine injection business In the event of Houttuynia cordata, nearly 100 enterprises' production lines were in the state of shutdown and half production, more than 10 enterprises were directly on the verge of bankruptcy, with a loss of about 2 billion yuan Although traditional Chinese medicine injection has been in an awkward position, it plays an irreplaceable role in the field of cardiovascular and cerebrovascular diseases and tumor diseases Cardiovascular and cerebrovascular diseases also accounted for 58.1% of the total market value of traditional Chinese medicine injection.